LSTA LISATA THERAPEUTICS, INC.
Price Chart
Executive Summary
Lisata Therapeutics amended its merger agreement with Kuva Labs, reducing the upfront cash consideration from $5.00 to $4.00 per share but increasing the maximum contingent value right (CVR) payout from $1.00 to $3.00 per share, split into a $1.25 milestone upon enrollment/completion of a Phase 2a GBM trial and a $1.75 milestone upon an NDA filing. The tender offer is set to commence June 1, 2026, with the outside date extended to July 6, 2026. This is a renegotiation that lowers guaranteed cash but offers higher potential upside tied to clinical and regulatory milestones.
Actionable Insight
The lower upfront cash is a clear negative for near-term value, but the increased CVR upside creates a binary catalyst tied to the Phase 2a GBM trial. Monitor enrollment updates for LSTA1-GBM-2A closely — the First Milestone ($1.25/share) could trigger by December 15, 2026 if enrollment completes. The non-tradeable CVRs mean holders must retain shares through closing to participate.
Key Facts
- Upfront cash consideration reduced from $5.00 to $4.00 per share (a 20% decrease)
- Maximum CVR payout increased from $1.00 to $3.00 per share ($1.25 First Milestone + $1.75 Second Milestone)
- First Milestone: enrollment completion, 90% enrollment, or termination of Phase 2a GBM trial (LSTA1-GBM-2A)
- Second Milestone: filing/acceptance of an NDA for certepetide (formerly LSTA1/CEND-1)
- CVRs are non-tradeable and expire on the 7th anniversary of closing
- Tender offer to commence June 1, 2026; outside date extended to July 6, 2026
- Interest accrues at the lesser of 10% p.a. or SOFR+5% on late First Milestone payments
Financial Impact
Guaranteed cash per share reduced by $1.00 (20% decrease), offset by up to $2.00 additional contingent consideration per share. Total maximum consideration per share is $7.00 ($4.00 cash + $3.00 CVRs) vs. $6.00 previously ($5.00 cash + $1.00 CVR).
Risk Factors
- Phase 2a GBM trial may fail to enroll or be terminated without milestone achievement
- CVRs are non-tradeable and expire worthless if milestones are not met within 7 years
- Kuva Labs may not complete the tender offer or merger despite the amendment
- Regulatory approval for certepetide is uncertain and years away
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-023336 |
| Document: ef20075162_8k.htm | 0001140361-26-023336 |
| Document: ef20075162_ex2-1.htm | 0001140361-26-023336 |
| Document: 0001140361-26-023336-index-headers.html | 0001140361-26-023336 |
| Document: 0001140361-26-023336-index.html | 0001140361-26-023336 |
| Document: 0001140361-26-023336.txt | 0001140361-26-023336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
3d ago
|
Press Release
| $3.45 awaiting T+5 | awaiting T+5 | — | $3.56 (+3.34%) |
|
Jun 9, 2026
4d ago
|
8-K
| $3.45 awaiting T+5 | awaiting T+5 | — | $3.56 (−3.34%) |
|
Jun 1, 2026
12d ago
|
8-K
| $3.58 $3.35 | ▲ +6.42% | ▲ +3.67% | $3.56 (+0.56%) |
|
May 29, 2026
14d ago
|
8-K
| $3.58 $3.35 | ▼ −6.42% | ▼ −3.67% | $3.56 (−0.56%) |
|
Apr 15, 2026
8w ago
|
8-K
| $3.37 $3.33 | ▲ +1.19% | ▲ +2.17% | $3.56 (−5.64%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $5.04 $5.04 | · 0.00% | ▲ +1.35% | $3.56 (−29.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access